Thrombocytopenia in lupus: baseline C3 as an independent risk factor for relapse
- 1 January 2007
- journal article
- letter
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 66 (1) , 130-131
- https://doi.org/10.1136/ard.2006.059758
Abstract
From 1995 to 2004, 38 consecutive patients with SLE with a first episode of thrombocytopenia (platelet count 8 C3 level, type of treatment and organ involvement were recorded at onset of thrombocytopenia. Relapse was twice defined as a drop in platelet count 150 000). Severe thrombocytopenia (<20 000/μl) was recorded in 34.2% of patients with rare haemorrhagic manifestations. Organ involvement included, in descending order, arthritis (31.6%), renal disease (29%), rash (18.5%), manifestations of the central nervous system (13.2%) and serositis (9%). Low C3 levels …This publication has 9 references indexed in Scilit:
- Lupus thrombocytopenia: clinical implications and prognostic significanceAnnals of the Rheumatic Diseases, 2005
- Outcome of Splenectomy for Thrombocytopenia Associated With Systemic Lupus ErythematosusAnnals of Surgery, 2004
- Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetilLupus, 2003
- Long-term effectiveness of danazol corticosteroids and cytotoxic drugs in the treatment of hematologic manifestations of systemic lupus erythematosus.Lupus, 2003
- Effective B Cell Depletion with Rituximab in the Treatment of Autoimmune DiseasesImmunobiology, 2002
- Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases.2002
- A decrease in complement is associated with increased renal and hematologic activity in patients with systemic lupus erythematosusArthritis & Rheumatism, 2001
- The validity of the ECLAM index for the retrospective evaluation of disease activity in systemic lupus erythematosusLupus, 2000
- Intermittent Cyclophosphamide for the Treatment of Autoimmune Thrombocytopenia in Systemic Lupus ErythematosusAnnals of Internal Medicine, 1990